PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING
2008
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI